S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Bausch Health Companies Stock Forecast, Price & News

+0.37 (+1.19%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
535,323 shs
Average Volume
443,725 shs
Market Capitalization
C$11.34 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BHC News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

Bausch Health Companies logo

About Bausch Health Companies

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.


Bausch Health Companies (TSE:BHC) Stock Price Down 2.1%
January 11, 2022 |  americanbankingnews.com
Eyeing Bausch Health? The Stock Needs Some Primary Care
December 15, 2021 |  finance.yahoo.com
Bausch Health Companies Inc.
December 3, 2021 |  baystreet.ca
See More Headlines

Industry, Sector and Symbol

Drug Manufacturers - Specialty & Generic
Year Founded

Sales & Book Value

Annual Sales
C$8.45 billion
Cash Flow
C$1.76 per share
Book Value
C($0.57) per share


Pretax Margin




Free Float
Market Cap
C$11.34 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)


Overall MarketRank

1.91 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Bausch Health Companies (TSE:BHC) Frequently Asked Questions

Is Bausch Health Companies a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bausch Health Companies stock.
View analyst ratings for Bausch Health Companies
or view top-rated stocks.

How has Bausch Health Companies' stock price been impacted by COVID-19?

Bausch Health Companies' stock was trading at C$25.34 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BHC shares have increased by 24.5% and is now trading at C$31.55.
View which stocks have been most impacted by COVID-19

When is Bausch Health Companies' next earnings date?

Bausch Health Companies is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Bausch Health Companies

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (TSE:BHC) announced its earnings results on Tuesday, November, 2nd. The company reported $1.44 EPS for the quarter, beating the Zacks' consensus estimate of $1.35 by $0.09. The business earned $2.66 billion during the quarter, compared to analyst estimates of $2.71 billion.
View Bausch Health Companies' earnings history

What price target have analysts set for BHC?

2 Wall Street analysts have issued twelve-month target prices for Bausch Health Companies' stock. Their forecasts range from C$44.00 to C$51.50. On average, they expect Bausch Health Companies' share price to reach C$47.75 in the next year. This suggests a possible upside of 51.3% from the stock's current price.
View analysts' price targets for Bausch Health Companies
or view top-rated stocks among Wall Street analysts.

Who are Bausch Health Companies' key executives?

Bausch Health Companies' management team includes the following people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 65, Pay $3.74M)
  • Ms. Christina M. Ackermann, Exec. VP, Gen. Counsel & Head of Commercial Operations (Age 56, Pay $1.31M)
  • Mr. Paul S. Herendeen, Exec. VP and Advisor to Chairman & CEO (Age 65, Pay $2.1M)
  • Mr. Thomas J. Appio, Pres & Co-Head Bausch + Lomb/International (Age 59, Pay $2.16M)
  • Mr. Osama A. Eldessouky, CFO & Exec. VP (Age 49)
  • Mr. Frederick J. Munsch, Controller & Chief Accounting Officer (Age 51)
  • Dr. Robert F. Butz, VP of Medical & Scientific Affairs
  • Mr. Arthur J. Shannon, Sr. VP and Head of Investor Relations & Global Communications
  • Mr. Michael McMyne, VP of Sales
  • Ms. Stacey Williams, VP of Marketing

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Chesapeake Energy (CHKAQ), Enbridge (ENB), Aurora Cannabis (ACB), Manulife Financial (MFC), BlackBerry (BB), Bank of Nova Scotia (BNS), Toronto-Dominion Bank (TD), Nutrien (NTR), Suncor Energy (SU) and ARC Resources (ARX).

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the Toronto Stock Exchange (TSX) under the ticker symbol "BHC."

How do I buy shares of Bausch Health Companies?

Shares of BHC and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately C$31.55.

How much money does Bausch Health Companies make?

Bausch Health Companies has a market capitalization of C$11.34 billion and generates C$8.45 billion in revenue each year.

How many employees does Bausch Health Companies have?

Bausch Health Companies employs 21,600 workers across the globe.

What is Bausch Health Companies' official website?

The official website for Bausch Health Companies is www.valeant.com.

Where are Bausch Health Companies' headquarters?

Bausch Health Companies is headquartered at 2150 Saint-Elzear Blvd W, Laval, Quebec H7L 4A8.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 Saint-Elzear Blvd W, Laval, Quebec H7L 4A8. The company can be reached via phone at 514-744-6792.

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.